Dr. Miller is the Chief Scientific Officer and is responsible for all facets of Artizan’s research and development organization and portfolio. Prior to joining Artizan in 2019, he was Chief Scientific Officer at Synlogic where he established the company’s research team and helped guide it to advance a novel, engineered, live microbial biotherapeutic platform from idea to first-in-human studies in under three years. Previously, Dr. Miller was the Vice President of Infection Biology at AstraZeneca where he was responsible for the early discovery portfolio and strategy, while also leading several external collaborations. Prior to AstraZeneca, Dr. Miller was the Chief Scientific Officer for Antibacterial Research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox and advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase 2 studies. A microbial geneticist by training, he began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated cutting edge molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Dr. Miller has served as a member of the Institute of Medicine’s Forum on Microbial Threats and also is a scientific advisor to the CARB-X antibacterial funding initiative as well as the Bill and Melinda Gates Foundation in the area of tuberculosis drug discovery. He received his Ph.D. in Microbiology and Immunology from the Albany Medical College and conducted post-doctoral studies in yeast genetics at the National Institutes of Health.